<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: additional risks", fill: "#f4bbff"},
{source: "2: additional risks", target: "2: uncertainties may also impair", fill: "#f4bbff"},
{source: "2: uncertainties may also impair", target: "2: operations", fill: "#f4bbff"},
{source: "2: additional risks", target: "3: following risks actually", fill: "#696969"},
{source: "3: following risks actually", target: "3: financial condition", fill: "#696969"},
{source: "3: financial condition", target: "3: operations may suffer", fill: "#696969"},
{source: "3: following risks actually", target: "7: undesired clinical", fill: "#0067a5"},
{source: "7: undesired clinical", target: "7: Contents ", fill: "#0067a5"},
{source: "7: Contents ", target: "7: development", fill: "#0067a5"},
{source: "7: development", target: "7: particular study", fill: "#0067a5"},
{source: "7: particular study", target: "7: patient enrollment", fill: "#0067a5"},
{source: "7: patient enrollment", target: "7: investigator recruitment", fill: "#0067a5"},
{source: "7: investigator recruitment", target: "7: obligations under", fill: "#0067a5"},
{source: "7: obligations under", target: "7: satisfy safety requirements", fill: "#0067a5"},
{source: "7: undesired clinical", target: "17: one client accounted", fill: "#2f847c"},
{source: "17: one client accounted", target: "17: service revenues", fill: "#2f847c"},
{source: "17: service revenues", target: "17: comparable period last year one client", fill: "#2f847c"},
{source: "17: comparable period last year one client", target: "17: December ", fill: "#2f847c"},
{source: "17: one client accounted", target: "113: common stock", fill: "#536895"},
{source: "113: common stock", target: "113: percentage ownership", fill: "#536895"},
{source: "113: percentage ownership", target: "113: voting power", fill: "#536895"},
{source: "113: voting power", target: "113: outstanding shares", fill: "#536895"},
{source: "113: common stock", target: "114: As of December ", fill: "#e4d96f"},
{source: "114: As of December ", target: "114: following capital structure", fill: "#e4d96f"},
{source: "114: following capital structure", target: "114: stock outstanding", fill: "#e4d96f"},
{source: "114: stock outstanding", target: "114: stock issuable upon", fill: "#e4d96f"},
{source: "114: stock issuable upon", target: "114: common stock outstanding", fill: "#e4d96f"},
{source: "114: common stock outstanding", target: "114: conversion", fill: "#e4d96f"},
{source: "114: conversion", target: "114: outstanding options", fill: "#e4d96f"},
{source: "114: outstanding options", target: "114: exercisable at", fill: "#e4d96f"},
{source: "114: exercisable at", target: "114: weighted average", fill: "#e4d96f"},
{source: "114: weighted average", target: "114: then exercisable", fill: "#e4d96f"},
{source: "114: As of December ", target: "119: common stock", fill: "#a81c07"},
{source: "119: common stock", target: "119: outstanding options upon", fill: "#a81c07"},
{source: "119: outstanding options upon", target: "119: exercise thereof could", fill: "#a81c07"},
{source: "119: exercise thereof could", target: "119: negative impact on", fill: "#a81c07"},
{source: "119: negative impact on", target: "119: market price", fill: "#a81c07"},
{source: "119: common stock", target: "START_HERE", fill: "#a81c07"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots. Italy still prohibits offensive strikes, and reserves the right to veto U.S. missions.2 JanuaryIndian aerial surveillance detected gunmen entering an Indian Air Force base at Pathankot, and their security forces exchange fire with them in a housing area.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Met_Operations">Met Operations</a></td>
      <td>Met Operations, also known as Met Ops, is one of the four business groups which forms the Metropolitan Police Service. It was created during the 2018-19 restructuring of the service, amalgamating many of its functions from the Operations side of the Specialist Crime &amp; Operations Directorate formed in 2012, with the Specialist Crime side of that Directorate placed under the new Frontline Policing Directorate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_7">December 7</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_Chopper_and_Market_32_Supermarkets">Price Chopper and Market 32 Supermarkets</a></td>
      <td>Golub Corporation is an American supermarket operator. Headquartered in Schenectady, New York, it owns the chains Market 32 and Price Chopper Supermarkets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BIO IMAGING TECHNOLOGIES INC      Item 1A Risk Factors          The more <font color="blue">prominent risks</font> and <font color="blue">uncertainties inherent</font> in our business are     described below</td>
    </tr>
    <tr>
      <td>However, <font color="blue"><font color="blue">additional</font> risks</font> and <font color="blue">uncertainties may also impair</font>     our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, our     business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font> may suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Investing     </font>in our <font color="blue">common stock</font> involves a high degree of risk</td>
    </tr>
    <tr>
      <td>Any of the following     <font color="blue">factors could harm</font> our business and future results of <font color="blue">operations</font> and you     <font color="blue">could lose</font> all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Company and Business          We <font color="blue">may incur financial losses</font> because <font color="blue">contracts may</font> be delayed or terminated     or reduced in scope for <font color="blue">reasons beyond</font> our control</td>
    </tr>
    <tr>
      <td>Our clients may terminate or delay their contracts for a variety of reasons,     including, but not limited to:           •   unexpected or <font color="blue">undesired clinical</font> results;                                           7     ______________________________________________________________________    [31]Table of <font color="blue">Contents       </font>  •   the client’s decision to terminate the <font color="blue">development</font> of a particular     product or to end a <font color="blue">particular study</font>;           •   insufficient <font color="blue">patient enrollment</font> in a study;           •   insufficient <font color="blue">investigator recruitment</font>;           •   failure to perform our <font color="blue">obligations under</font> the contract; or           •   the failure of products to <font color="blue">satisfy safety <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>In addition, we believe that FDA-regulated <font color="blue">companies may proceed with fewer</font>     <font color="blue">clinical trials</font> or <font color="blue">conduct them without assistance</font> of <font color="blue">contract service</font>     <font color="blue">organizations</font>  if  they are trying to <font color="blue">reduce costs as</font> a result of cost     containment pressures associated with healthcare reform, budgetary limits or     changing  priorities</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors may</font> cause <font color="blue">such companies</font> to cancel     contracts with <font color="blue">contract service</font> <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">clients will continue</font> to use our services or     that we will be able to replace, in a timely or effective manner, departing     <font color="blue">clients with new clients</font> that <font color="blue">generate comparable revenues</font></td>
    </tr>
    <tr>
      <td>Further, we     <font color="blue">cannot assure</font> you that our <font color="blue">clients will continue</font> to <font color="blue">generate consistent</font>     amounts of <font color="blue">revenues over</font> time</td>
    </tr>
    <tr>
      <td>The loss, reduction in scope or delay of a large contract or the loss or     delay of multiple contracts could <font color="blue">materially</font> <font color="blue">adversely</font> affect our business,     although our <font color="blue">contracts entitle us</font> to receive all <font color="blue">fees earned up</font> to the time     of <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>The loss of business from our client Novartis would have a     material adverse effect on our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We  depend  on a small number of <font color="blue">industries</font> and clients for all of our     business, and the loss of <font color="blue">one such <font color="blue">significant client</font> could</font> cause revenues     to <font color="blue">drop quickly</font> and <font color="blue">unexpectedly</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">depend on research</font> and <font color="blue">development</font> <font color="blue">expenditures</font> by <font color="blue">pharmaceutical</font>,     <font color="blue">bio<font color="blue">technology</font></font> and medical device companies to sustain our business</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font> if:           •   clients’ <font color="blue">businesses</font> experience <font color="blue">financial problems</font> or are <font color="blue">affected by</font> a     <font color="blue">general economic downturn</font>;           •   <font color="blue">consolidation</font> in the <font color="blue">pharmaceutical</font>, <font color="blue">bio<font color="blue">technology</font></font> or medical device     <font color="blue">industries</font> leads to a <font color="blue">smaller client base</font> for us; or           •   <font color="blue">clients reduce</font> their research and <font color="blue">development</font> <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>No <font color="blue">one client accounted</font> for 10prca or more of our <font color="blue">service revenues</font> for fiscal     2005,  while for the comparable period last year, one client, Novartis     Pharmaceuticals Corp, encompassing 18 distinct projects, amounted to 10prca of     <font color="blue">service revenues</font> for the year ended <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>The loss of business     from a <font color="blue">significant client</font> or our failure to continue to obtain new business     to replace completed or canceled projects would have a material adverse     effect on our business and revenues</td>
    </tr>
    <tr>
      <td>Our contracted/committed backlog may not be <font color="blue">indicative</font> of future results</td>
    </tr>
    <tr>
      <td>Our reported contracted/committed backlog of dlra58dtta4 million at <font color="blue">December </font>31,     2005 is <font color="blue">based on</font> anticipated <font color="blue">service revenue from uncompleted</font> projects with     clients</td>
    </tr>
    <tr>
      <td>Backlog is the amount of revenue that remains to be earned and     recognized on signed and <font color="blue">verbally agreed</font> to contracts</td>
    </tr>
    <tr>
      <td><font color="blue">Contracts </font>included in     backlog are subject to <font color="blue">termination</font> by our <font color="blue">clients at</font> any time</td>
    </tr>
    <tr>
      <td>In the event     that the client cancels a contract, we would be entitled to receive payment     for all services performed up to the <font color="blue">cancellation</font> date and <font color="blue">subsequent client</font>     <font color="blue">authorized services</font> related to the <font color="blue">cancellation</font> of the project</td>
    </tr>
    <tr>
      <td>The duration     of the projects included in our <font color="blue">backlog range from less than three months</font> to     <font color="blue">seven years</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that this <font color="blue">backlog will</font> be <font color="blue">indicative</font> of future     results</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors may</font> affect backlog, including:           •   the <font color="blue">variable size</font> and duration of the projects (some are performed     <font color="blue">over several years</font>);           •   the loss or delay of projects;                                           8     ______________________________________________________________________    [32]Table of <font color="blue">Contents       </font>  •   the change in the scope of work during the course of a project; and           •   the <font color="blue">cancellation</font> of <font color="blue">such contracts by</font> our clients</td>
    </tr>
    <tr>
      <td>Also, if <font color="blue">clients delay</font> projects, the projects will remain in backlog, but     will not <font color="blue">generate revenue at</font> the <font color="blue">rate originally</font> expected</td>
    </tr>
    <tr>
      <td>Accordingly,     <font color="blue">historical indications</font> of the <font color="blue">relationship</font> of backlog to revenues are not     <font color="blue">indicative</font> of future results</td>
    </tr>
    <tr>
      <td>We have experienced substantial expansion in the past, and if we fail to     <font color="blue">properly manage</font> that expansion, our business may suffer</td>
    </tr>
    <tr>
      <td>Our business has <font color="blue">expanded <font color="blue">substantially</font></font> in the past</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continuing sales</font>     and <font color="blue">marketing efforts</font> have increased the number of projects <font color="blue">under <font color="blue">management</font></font>     from 224 in fiscal 2004 to 270 in fiscal 2005</td>
    </tr>
    <tr>
      <td>We acquired <font color="blue">one company</font> in     November 2003 and another company in <font color="blue">December </font>2004</td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">expansion could</font>     strain  our  operational, human and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">properly manage</font> this expansion, our results of <font color="blue">operations</font> and financial     <font color="blue">condition might</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In order to manage our expansion, we     must:           •   <font color="blue">effectively market</font> our services to <font color="blue">pharmaceutical</font>, <font color="blue">bio<font color="blue">technology</font></font> and     medical device companies;           •   continue to improve operating, <font color="blue">administrative</font> and information systems;           •   <font color="blue">accurately predict future personnel</font> and resource needs to <font color="blue">meet client</font>     <font color="blue">contract commitments</font>;           •   <font color="blue"><font color="blue">successfully</font> integrate</font> our acquired companies and <font color="blue">businesses</font>;           •   track the progress of on-going client projects; and           •   attract and retain qualified <font color="blue">management</font>, sales, professional and     technical operating personnel</td>
    </tr>
    <tr>
      <td>We will face <font color="blue"><font color="blue">additional</font> risks</font> in expanding foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Specifically,     we might find it <font color="blue">difficult</font> to:           •   <font color="blue">assimilate differences</font> in foreign business practices and <font color="blue">regulations</font>;           •   hire and retain <font color="blue">qualified personnel</font>; and           •   <font color="blue">overcome language</font> and <font color="blue">cultural barriers</font></td>
    </tr>
    <tr>
      <td>We  may engage in future <font color="blue">acquisition</font>s, which may be expensive and time     consuming and from which we may not realize anticipated benefits</td>
    </tr>
    <tr>
      <td>We  may acquire <font color="blue">additional</font> <font color="blue">businesses</font>, technologies and products if we     determine  that these <font color="blue">additional</font> <font color="blue">businesses</font>, technologies and products     <font color="blue">complement</font> our existing business or <font color="blue">otherwise serve</font> our <font color="blue">strategic goals</font></td>
    </tr>
    <tr>
      <td>If     we do undertake <font color="blue">transactions</font> of this sort, the process of integrating an     acquired  business,  <font color="blue">technology</font>  or  product  may  result in operating     <font color="blue">difficult</font>ies  and  <font color="blue">expenditures</font>  and <font color="blue">may absorb significant <font color="blue">management</font></font>     attention that <font color="blue">would otherwise</font> be available for ongoing <font color="blue">development</font> of our     business</td>
    </tr>
    <tr>
      <td>Moreover, we may never realize the anticipated benefits of any     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">acquisition</font>s could result in <font color="blue">potentially dilutive</font>     issuances  of  our  securities,  the incurrence of debt and <font color="blue">contingent</font>     <font color="blue">li<font color="blue">abilities</font></font> and <font color="blue">amortization expenses</font> related to intangible assets, which     <font color="blue">could <font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Loss  of  key  personnel,  or failure to attract and retain <font color="blue">additional</font>     personnel, may cause the success and growth of our business to suffer</td>
    </tr>
    <tr>
      <td>Future  success  depends  on the <font color="blue">personal efforts</font> and <font color="blue">abilities</font> of the     <font color="blue">principal members</font> of our <font color="blue">senior <font color="blue">management</font></font> to <font color="blue">provide strategic direction</font>,     develop business, manage <font color="blue">operations</font> and maintain a cohesive and stable     <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>Specifically,  we  are <font color="blue">dependent upon</font> Mark L Weinstein,     President  and  Chief  Executive Officer, David A Pitler, Senior Vice     President Operations, Colin G Miller, Ph</td>
    </tr>
    <tr>
      <td>Although we have                                           9     ______________________________________________________________________    [33]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue"><font color="blue">employment</font> <font color="blue">agreement</font>s</font> with</font> Mr</td>
    </tr>
    <tr>
      <td><font color="blue">Weinstein and Mr</font></td>
    </tr>
    <tr>
      <td>Kaminer, this does not     <font color="blue">necessarily mean</font> that they <font color="blue">will remain with us</font></td>
    </tr>
    <tr>
      <td>Although we have executive     <font color="blue">retention <font color="blue">agreement</font>s with</font> our officers, we do not have <font color="blue"><font color="blue">employment</font> <font color="blue">agreement</font>s</font>     with any other <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">performance also depends on</font>     our ability to attract and retain <font color="blue">management</font> and <font color="blue">qualified professional</font> and     technical  operating staff</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for these skilled personnel is     intense</td>
    </tr>
    <tr>
      <td>The loss of services of any <font color="blue">key executive</font>, or <font color="blue">inability</font> to continue     to attract and retain qualified staff, could have a material adverse effect     on our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We do not     maintain any <font color="blue">key employee insurance on</font> any of our <font color="blue">executives</font></td>
    </tr>
    <tr>
      <td>Our revenues, earnings and operating costs are exposed to <font color="blue">exchange rate</font>     <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>In fiscal 2005, a small portion of our <font color="blue">service revenues</font> were <font color="blue">denominated</font> in     <font color="blue">foreign currency</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial statements</font> are <font color="blue">denominated</font> in <font color="blue"><font color="blue">United States </font>    </font>dollars</td>
    </tr>
    <tr>
      <td>In  the  event a greater portion of our <font color="blue">service revenues</font> are     <font color="blue">denominated</font> in a <font color="blue">foreign currency</font> changes in <font color="blue">foreign currency</font> <font color="blue">exchange rate</font>s     <font color="blue">could affect</font> our results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations     </font>in <font color="blue">foreign currency</font> <font color="blue">exchange rate</font>s could <font color="blue">materially</font> impact the operating     costs  of  our  European <font color="blue">facility</font> in Leiden, the Netherlands which are     primarily EURO <font color="blue">denominated</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry          Our failure to <font color="blue">compete effectively</font> in the <font color="blue">competitive industry could</font> cause     our revenues to decline</td>
    </tr>
    <tr>
      <td><font color="blue">Significant  </font>factors in determining whether we will be able to compete     <font color="blue">successfully</font> include:           •   <font color="blue">consultative</font> and <font color="blue">clinical trials</font> design cap<font color="blue">abilities</font>;           •   reputation for on-time quality performance;           •   expertise and experience in <font color="blue">specific therapeutic areas</font>;           •   the scope of service offerings;           •   strength in <font color="blue">various geographic markets</font>;           •   the price of services;           •   ability to acquire, process, analyze and report data in a time-saving     and accurate manner;           •   ability to manage large-scale <font color="blue">clinical trials</font> both domestically and     <font color="blue">internationally</font>;           •   our size; and           •   the service and <font color="blue">product offerings</font> of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>If our services are not competitive <font color="blue">based on</font> these or other factors, our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> will be <font color="blue">materially</font>     harmed</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">pharmaceutical</font> services industry</font> is <font color="blue">highly competitive</font>, and we face     numerous  <font color="blue">competitors</font>  in our business, including hundreds of contract     research <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">compete effectively</font>, we will lose     clients, which would cause our business to suffer</td>
    </tr>
    <tr>
      <td>We <font color="blue">primarily compete</font>     against in-house departments of <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, full service     contract research <font color="blue">organizations</font>, or CROs, small specialty CROs, and to a     lesser  extent,  <font color="blue">universities</font>  and  teaching  hospitals</td>
    </tr>
    <tr>
      <td>Some of these     <font color="blue">competitors</font>  have  <font color="blue">substantially</font>  greater capital, technical and other     <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>In addition, certain of our <font color="blue">competitors</font> that are     smaller specialized companies may <font color="blue">compete effectively</font> against us because of     their <font color="blue">concentrated size</font> and focus</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in outsourcing trends in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     <font color="blue">industries</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our operating results and <font color="blue">growth rate</font></td>
    </tr>
    <tr>
      <td><font color="blue">Service  </font>revenues  depend  greatly  on  the  <font color="blue">expenditures</font>  made by the     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font> in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">economic factors</font> and <font color="blue">industry trends</font> that affect our clients                                           10     ______________________________________________________________________    [34]Table of <font color="blue">Contents       </font>in these <font color="blue">industries</font> also affect our business</td>
    </tr>
    <tr>
      <td>For example, the practice of     many companies in these <font color="blue">industries</font> has been to hire outside <font color="blue">organizations</font>     like us to <font color="blue">conduct clinical research</font> projects</td>
    </tr>
    <tr>
      <td>This practice has grown     <font color="blue">significantly</font> in the last decade, and we have <font color="blue">benefited from</font> this trend</td>
    </tr>
    <tr>
      <td>However, if this trend were to change and companies in these <font color="blue">industries</font> were     to reduce the number of research and <font color="blue">development</font> projects they outsource,     our business could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Additionally,  <font color="blue">numerous governments</font> have <font color="blue">undertaken efforts</font> to control     growing healthcare costs through <font color="blue">legislation</font>, regulation and voluntary     <font color="blue"><font color="blue">agreement</font>s with medical care providers</font> and <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">future regulatory cost containment efforts limit</font> the profits that can be     derived  on  new  drugs,  our  <font color="blue">clients might reduce</font> their research and     <font color="blue">development</font> spending, which could reduce our business</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> existing <font color="blue">regulations</font> could result in increased costs     to complete <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Our business is subject to numerous <font color="blue">governmental</font> <font color="blue">regulations</font>, primarily     relating to <font color="blue">pharmaceutical</font> product <font color="blue">development</font> and the conduct of clinical     trials</td>
    </tr>
    <tr>
      <td>In particular, we are subject to 21 CFR Part 11 of the Code of     <font color="blue">Federal Regulations </font>that provides the criteria for <font color="blue"><font color="blue">acceptance</font> by</font> the FDA of     <font color="blue">electronic</font>  records</td>
    </tr>
    <tr>
      <td>If  we  fail  to  <font color="blue">comply with</font> these <font color="blue">governmental</font>     <font color="blue">regulations</font>, it could result in the <font color="blue">termination</font> of <font color="blue">ongoing clinical research</font>     or the <font color="blue">disqualification</font> of data for submission to <font color="blue">regulatory authorities</font></td>
    </tr>
    <tr>
      <td>We     also could be <font color="blue">barred from providing clinical trial services</font> in the future or     be subjected to fines</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">consequences</font> would harm our reputation,     our prospects for future work and our operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Our CapMed </font>division may not <font color="blue">reach profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our CapMed </font>division had a loss from <font color="blue">operations</font> of dlra1cmam107cmam850 in fiscal 2005</td>
    </tr>
    <tr>
      <td>If our CapMed division continues to <font color="blue">incur such losses</font>, our <font color="blue">businesses</font>,     results of <font color="blue">operations</font> and <font color="blue">financial condition</font> could be <font color="blue">materially</font> <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">governmental</font> regulation could decrease the need for the services     we provide, which would <font color="blue">negatively</font> affect our future business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the <font color="blue"><font color="blue">United States </font>Congress </font>and state <font color="blue">legislatures</font> have     considered various types of healthcare reform in order to control growing     healthcare costs</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">United States </font>Congress </font>and state <font color="blue">legislatures</font> may     again address healthcare reform in the future</td>
    </tr>
    <tr>
      <td>We are unable to predict what     <font color="blue">legislative proposals will</font> be adopted in the future, if any</td>
    </tr>
    <tr>
      <td>Similar reform     movements have occurred in <font color="blue">Europe and Asia</font></td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of healthcare reform <font color="blue">legislation</font> that results in <font color="blue">additional</font>     costs  could  limit  the  profits that can be made by clients from the     <font color="blue">development</font>  of new products</td>
    </tr>
    <tr>
      <td>This <font color="blue">could <font color="blue">adversely</font> affect</font> our clients’     research and <font color="blue">development</font> <font color="blue">expenditures</font>, which could, in turn, decrease the     business <font color="blue">opportunities</font> available to us both in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>In  addition,  new laws or <font color="blue">regulations</font> may create a risk of <font color="blue">liability</font>,     <font color="blue">increase costs</font> or <font color="blue">limit service offerings</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood     of any of these events</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">healthcare reform proposals</font>, the expansion of <font color="blue">managed care</font>     <font color="blue">organizations</font> in the <font color="blue">healthcare market may</font> result in <font color="blue">reduced spending on</font>     research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Managed care <font color="blue">organizations</font>’ efforts to cut costs     by limiting <font color="blue">expenditures</font> on <font color="blue">pharmaceutical</font>s and medical devices could result     in <font color="blue">pharmaceutical</font>, <font color="blue">bio<font color="blue">technology</font></font> and medical device <font color="blue">companies spending less</font>     on research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If this were to occur, we would have fewer     business <font color="blue">opportunities</font> and our revenues could decrease, possibly <font color="blue">materially</font></td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue">agencies throughout</font> the world, but particularly in the United     States,  strictly  regulate the drug <font color="blue">development</font>/approval process</td>
    </tr>
    <tr>
      <td>Our     business  involves  helping <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies     navigate the <font color="blue">regulatory drug approval process</font></td>
    </tr>
    <tr>
      <td>Changes in regulation, such     as <font color="blue">relaxation</font> in <font color="blue">regulatory <font color="blue">requirements</font></font> or the <font color="blue">introduction</font> of simplified     <font color="blue">drug approval procedures</font> or an increase in <font color="blue">regulatory <font color="blue">requirements</font></font> that we     may have <font color="blue">difficult</font>y satisfying <font color="blue">could eliminate</font> or <font color="blue">substantially</font> reduce the     need for our services</td>
    </tr>
    <tr>
      <td>If these                                           11     ______________________________________________________________________    [35]Table of <font color="blue">Contents       </font>changes in <font color="blue">regulations</font> were to occur, our business, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font> could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>These and     other changes in regulation could have a material adverse impact on our     available business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">governmental</font> agencies do not accept the data and <font color="blue">analyses generated by</font>     our services, the need for our <font color="blue">services would</font> be eliminated or <font color="blue">substantially</font>     reduced</td>
    </tr>
    <tr>
      <td>The success of our business is <font color="blue">dependent upon</font> continued <font color="blue"><font color="blue">acceptance</font> by</font> the     FDA and other <font color="blue">regulatory authorities</font> of the data and <font color="blue">analyses generated by</font>     our services in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">evaluation</font> of the safety and efficacy of     new drugs and devices</td>
    </tr>
    <tr>
      <td>The FDA has formal guidelines that encourage the use     of “surrogate measures,” through submission of <font color="blue">digital image data</font>, for     <font color="blue">evaluation</font> of drugs to treat life-threatening or <font color="blue">debilitating conditions</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that the FDA or other <font color="blue">regulatory authorities</font> will accept     the  data or <font color="blue">analyses generated by</font> us in the future and, even assuming     <font color="blue">acceptance</font>, the FDA or other <font color="blue">regulatory authorities</font> may not require the     <font color="blue">application</font> of <font color="blue">imaging techniques</font> to numbers of patients and over time     periods <font color="blue">substantially</font> similar to those required of <font color="blue">traditional safety</font> and     <font color="blue">efficacy techniques</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">governmental</font> agencies do not accept data and     <font color="blue">analyses generated by</font> our services in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">evaluation</font> of new     drugs  and  devices,  the need for our <font color="blue">services would</font> be eliminated or     <font color="blue">substantially</font> reduced, and, as a result, our business, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font> could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">liability</font> claims as a result of our <font color="blue">involvement</font> in     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">liability</font> claims as a result of our <font color="blue">involvement</font> in     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">liability</font> claims will not be     asserted  <font color="blue">against us as</font> a result of work performed for our clients</td>
    </tr>
    <tr>
      <td>We     maintain  <font color="blue">liability</font>  <font color="blue">insurance coverage</font> in amounts that we believe are     sufficient for the <font color="blue">pharmaceutical</font> services industry</td>
    </tr>
    <tr>
      <td>Furthermore, we cannot     assure you that our <font color="blue">clients will agree</font> to <font color="blue">indemnify us</font>, or that we will have     <font color="blue">sufficient insurance</font> to satisfy any such <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>If a claim is     brought against us and the outcome is unfavorable to us, such outcome could     have a material <font color="blue">adverse impact on us</font></td>
    </tr>
    <tr>
      <td>Risks related to our <font color="blue">common stock</font>          Your <font color="blue">percentage ownership</font> and <font color="blue">voting power</font> and the price of our <font color="blue">common stock</font>     may  decrease  as  a  result of events that increase the number of our     <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had the <font color="blue">following capital structure</font>:                          Common <font color="blue">stock outstanding</font>                                                       11cmam167cmam737                            Common <font color="blue">stock issuable upon</font>:                Exercise of options which are outstanding                                                        1cmam831cmam308                  Exercise of options which have not been granted                                                          895cmam383    Total <font color="blue">common stock</font> outstanding assuming exercise or <font color="blue">conversion</font> of all of the                                     above                                                       13cmam894cmam428         As of <font color="blue">December </font>31, 2005, we had <font color="blue">outstanding options</font> to purchase 1cmam831cmam308     shares of <font color="blue">common stock</font> at exercise prices ranging from dlra0dtta63 to dlra7dtta03 per     share (<font color="blue">exercisable at</font> a <font color="blue">weighted average</font> of dlra2dtta30 per share), of which     1cmam753cmam558 options were <font color="blue">then exercisable</font></td>
    </tr>
    <tr>
      <td>Exercise of our <font color="blue">outstanding options</font>     into our <font color="blue">common stock</font> may <font color="blue">significantly</font> and <font color="blue">negatively</font> affect the market     price for our <font color="blue">common stock</font> as well as decrease your <font color="blue">percentage ownership</font> and     <font color="blue">voting power</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">may conduct future offerings</font> of our common     stock or other <font color="blue">securities with rights</font> to convert the <font color="blue">securities into shares</font>     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result of these and other events that increase the     number of our <font color="blue">outstanding shares</font>, your <font color="blue">percentage ownership</font> and <font color="blue">voting power</font>     and the price of our <font color="blue">common stock</font> may decrease</td>
    </tr>
    <tr>
      <td>Future sales of shares of our <font color="blue">common stock</font> by existing holders of our common     stock or by holders of <font color="blue">outstanding options</font>, upon the exercise thereof, could     have  a <font color="blue">negative impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we had 11cmam167cmam737 shares of our <font color="blue">common stock</font> issued and     outstanding, all of which are <font color="blue">currently freely tradable</font></td>
    </tr>
    <tr>
      <td>Pursuant to his     <font color="blue">employment</font> <font color="blue">agreement</font>, on January 31, 2005, we issued 30cmam000 restricted     shares of our <font color="blue">common stock</font> to an <font color="blue">executive officer</font></td>
    </tr>
    <tr>
      <td>We are unable to estimate the number of shares that may be sold since this     will  depend  on  the  <font color="blue">market price</font> for our <font color="blue">common stock</font>, the personal     <font color="blue">circumstances</font> of the sellers and other factors</td>
    </tr>
    <tr>
      <td>Any sale of substantial     amounts of our <font color="blue">common stock</font> or other securities in the <font color="blue">open market may</font>     <font color="blue">adversely</font> affect the <font color="blue">market price</font> of the <font color="blue">securities offered hereby</font> and may     <font color="blue">adversely</font> affect our ability to obtain <font color="blue">future financing</font> in the capital     <font color="blue">markets as well as</font> create a <font color="blue">potential market overhang</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">affiliates</font> have <font color="blue">significant control over</font> our <font color="blue">common stock</font>, allowing them     to have <font color="blue">significant influence over</font> the outcome of all <font color="blue">matters submitted</font> to     our  <font color="blue">stockholders</font>  for approval, which influence may conflict with our     interests and the interests of our other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">directors</font>, officers and principal <font color="blue">stockholders</font> (<font color="blue">stockholders</font> owning 10prca     or more of our <font color="blue">common stock</font>), including Covance Inc, <font color="blue">beneficially</font> owned 47prca     of the <font color="blue">outstanding shares</font> of <font color="blue">common stock</font> on a fully diluted as-converted to     <font color="blue">common stock</font> basis at <font color="blue">December </font>31, 2005, and such <font color="blue">stockholders</font> will have     <font color="blue">significant influence over</font> the outcome of all <font color="blue">matters submitted</font> to our     <font color="blue">stockholders</font> for approval, including the election of our <font color="blue">directors</font> and other     <font color="blue">corporate actions</font></td>
    </tr>
    <tr>
      <td>In addition, such influence by these <font color="blue">affiliates</font> could     have the effect of <font color="blue">discouraging others from attempting</font> to take us over,     <font color="blue">thereby increasing</font> the likelihood that the <font color="blue">market price</font> of the <font color="blue">common stock</font>     will not reflect a premium for control</td>
    </tr>
    <tr>
      <td>Because we do not intend to pay dividends, <font color="blue">stockholders</font> will benefit from an     <font color="blue">investment</font> in our <font color="blue">common stock</font> only if it appreciates in value</td>
    </tr>
    <tr>
      <td>We have never declared or paid any <font color="blue"><font color="blue">cash dividends</font> on</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>, if any, to <font color="blue">finance further</font>     research and <font color="blue">development</font> and do not expect to pay any <font color="blue">cash dividends</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>As a result, the success of an <font color="blue">investment</font> in our common     <font color="blue">stock will depend upon</font> any <font color="blue">future appreciation</font> in its value</td>
    </tr>
    <tr>
      <td>There is no     guarantee that our <font color="blue">common stock</font> will appreciate in value or even maintain     the price at which <font color="blue">stockholders</font> have purchased their shares</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has experienced <font color="blue">historical <font color="blue">volatility</font></font>     and <font color="blue">might continue</font> to experience <font color="blue">volatility</font> in the future in response to     quarter-to-quarter variations in:           •   operating results;           •   analysts’ reports;           •   <font color="blue">market conditions</font> in the industry;           •   changes in <font color="blue">governmental</font> <font color="blue">regulations</font>; and           •   changes in <font color="blue">general conditions</font> in the economy or the <font color="blue">financial markets</font></td>
    </tr>
    <tr>
      <td>The  market  has also experienced <font color="blue">significant decreases</font> in value</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">volatility</font> and the <font color="blue">recent market decline</font> has affected the <font color="blue">market price</font>s of     <font color="blue">securities issued by</font> many companies, often for <font color="blue">reasons unrelated</font> to their     operating performance, and may <font color="blue">adversely</font> affect the price of our common     stock</td>
    </tr>
    <tr>
      <td><font color="blue">Between January </font>1, 2005 and <font color="blue">December </font>31, 2005, our <font color="blue">common stock</font> has     traded at a low of dlra2dtta10 per share and a high of dlra5dtta51 per share</td>
    </tr>
    <tr>
      <td>Between     January 1, 2006 and <font color="blue">February </font>28, 2006, our <font color="blue">common stock</font> has traded at a low     of dlra3dtta11 per share and a high of dlra4dtta73 per share</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>Our <font color="blue">common stock</font> began trading on the <font color="blue">NASDAQ National Market </font>on <font color="blue">December </font>18,     2003 and has a limited <font color="blue">trading market</font></td>
    </tr>
    <tr>
      <td>Prior to that time, our <font color="blue">common stock</font>     was trading on <font color="blue">the American Stock Exchange </font>since <font color="blue">February </font>2003</td>
    </tr>
    <tr>
      <td>We cannot     assure that an active <font color="blue">trading market</font> will develop or, if developed, will be     maintained</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">stockholders</font> may find it <font color="blue">difficult</font> to dispose     of shares of our <font color="blue">common stock</font> and, as a result, may suffer a loss of all or     a substantial portion of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Certain provisions of our charter and <font color="blue">Delaware </font>law could make a takeover     <font color="blue">difficult</font> and <font color="blue">may prevent</font> or <font color="blue">frustrate attempts by</font> our <font color="blue">stockholders</font> to     replace or remove our <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>We have an authorized class of 1cmam750cmam000 shares of <font color="blue">undesignated preferred</font>     stock that may be issued by our board of <font color="blue">directors</font>, on such terms and with     such  rights,  <font color="blue">preferences</font> and <font color="blue">designation as</font> the Board may determine</td>
    </tr>
    <tr>
      <td>Issuance of such preferred stock, depending upon the rights, <font color="blue">preferences</font> and     <font color="blue">designations</font>  thereof,  may  have the effect of delaying, deterring or     preventing a change in control of our company</td>
    </tr>
    <tr>
      <td>In addition, we are subject     to  provisions  of  <font color="blue">Delaware </font> corporate  law which, subject to certain     exceptions, will prohibit us from engaging in any “business <font color="blue">combination</font>”     with a person who, together with <font color="blue">affiliates</font> and <font color="blue">associates</font>, owns 15prca or more     of our <font color="blue">common stock</font> for a period of <font color="blue">three years following</font> the date that the     person came to own 15prca or more of our <font color="blue">common stock</font> unless the business     <font color="blue">combination</font> is approved in a <font color="blue">prescribed manner</font></td>
    </tr>
    <tr>
      <td>These provisions of our <font color="blue">certificate</font> of incorporation, and of <font color="blue">Delaware </font>law     may have the effect of delaying, deterring or preventing a change in control     of our company, may discourage bids for our <font color="blue">common stock</font> at a <font color="blue">premium over</font>     <font color="blue">market price</font> and may <font color="blue">adversely</font> affect the <font color="blue">market price</font>, and the voting and     other  rights  of the holders, of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, these     provisions  make  it  more  <font color="blue">difficult</font> to replace or remove our current     <font color="blue">management</font> team in the event our <font color="blue">stockholders</font> believe this would be in the     <font color="blue">best interest</font> of our company and our <font color="blue">stockholders</font></td>
    </tr>
  </tbody>
</table>